Arcutis Biotherapeutics - ARQT Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARQT shares.
View ARQT analyst ratings or view top-rated stocks.

6 brokerages have issued twelve-month price targets for Arcutis Biotherapeutics' shares. Their ARQT share price forecasts range from $45.00 to $57.00. On average, they expect the company's stock price to reach $50.40 in the next year. This suggests a possible upside of 176.8% from the stock's current price.
View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts.

Arcutis Biotherapeutics' stock was trading at $20.74 on January 1st, 2022. Since then, ARQT shares have decreased by 12.2% and is now trading at $18.21.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ARQT earnings forecast.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($1.31) EPS for the quarter, beating analysts' consensus estimates of ($1.38) by $0.07.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

(ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager.

Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol "ARQT."

Arcutis Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.96%), Bain Capital Life Sciences Investors LLC (5.82%), Point72 Asset Management L.P. (3.85%), State Street Corp (2.71%), Pictet Asset Management SA (1.79%) and Franklin Resources Inc. (1.54%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Howard G Welgus, John W Smither, Jonathan Silverstein, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends.

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARQT stock can currently be purchased for approximately $18.21.

Arcutis Biotherapeutics (NASDAQ:ARQT) has a market capitalization of $938.96 million. The company earns $-206,360,000.00 in net income (profit) each year or ($5.14) on an earnings per share basis.

The company employs 147 workers across the globe.

Arcutis Biotherapeutics' mailing address is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. The official website for the company is www.arcutis.com. The company can be reached via phone at 805-418-5006 or via email at ir@arcutis.com.